IRLAB presents ISP at the CNS and Neurodegenerative Targets conference in Boston
IRLAB’s research platform, the Integrative Screening Process – ISP, is gaining increased international interest. ISP will be presented at the CNS and Neurodegenerative Targets conference in Boston, 26-27 September 2018.
IRLAB is invited to present at the conference and participates with the presentation "Evolving the Concept of Phenotypic Screening to a New Level of Data-Driven, Systems Oriented Drug Discovery". The presentation is held by Peder Svensson, PhD – Director of Computational Chemistry & Biology, CIO. More information about the ISP is available on IRLAB’s website, www.irlab.se/isp-platform, and in the published article in ACS Chemical Neuroscience, www.bit.ly/IRLAB_ACS.
The conference aims at highlighting the latest research tools and platforms driving today's CNS drug discovery strategies. For more information, see the conference website, www.discoverytarget.com/CNS-Neurodegenerative-Targets.